Alnylam announces innovative value-based agreement framework for oxlumo™ (lumasiran) to accelerate access for patients with primary hyperoxaluria type 1 and deliver ultra-rare orphan disease pricing solutions to u.s. payers

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today a new framework for value-based agreements (vbas) designed to help people with primary hyperoxaluria type 1 (ph1) gain access to oxlumo™ (lumasiran). now approved by the u.s. food and drug administration (fda) for the treatment of ph1 to lower urinary oxalate levels in pediatric and adult patients, oxlumo is the first-ever approved targeted therapeutic that sub
ALNY Ratings Summary
ALNY Quant Ranking